Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy.
This report offers an overview of the market trends, drivers, and barriers with respect to the USA Postmenopausal Vaginal Atrophy Drugs market. It also provides a detailed overview of the market of different regions across West USA, South USA, Middle West USA, Northeast USA. The report deeply analyzes type and application in the USA Postmenopausal Vaginal Atrophy Drugs market. Detailed analysis of key players, along with key growth strategies adopted by Postmenopausal Vaginal Atrophy Drugs industry, the PEST and SWOT analysis are also included. In short, the report will provide a comprehensive view of the industry's development and features.
By Player:
Actavis plc
Novo Nordisk A/S
Shionogi & Company
Allergan plc
By Type:
Premarin
Vagifem
Estrace
Estring
Femring
By End-User:
Vaginal Gels
Creams
Tablets
Rings
Patches
By Region:
-
West USA
-
South USA
-
Middle West USA
-
Northeast USA
TABLE OF CONTENT
1 Report Overview
-
1.1 Product Definition and Scope
-
1.2 PEST (Political, Economic, Social and Technological) Analysis of Postmenopausal Vaginal Atrophy Drugs Market
-
1.3 Market Segment by Type
-
1.3.1 USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Premarin from 2016 to 2027
-
1.3.2 USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Vagifem from 2016 to 2027
-
1.3.3 USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Estrace from 2016 to 2027
-
1.3.4 USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Estring from 2016 to 2027
-
1.3.5 USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Femring from 2016 to 2027
-
1.4 Market Segment by Application
-
1.4.1 USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Vaginal Gels from 2016 to 2027
-
1.4.2 USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Creams from 2016 to 2027
-
1.4.3 USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Tablets from 2016 to 2027
-
1.4.4 USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Rings from 2016 to 2027
-
1.4.5 USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Patches from 2016 to 2027
-
1.5 Market Segment by Regions
-
1.5.1 West USA Postmenopausal Vaginal Atrophy Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.2 South USA Postmenopausal Vaginal Atrophy Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.3 Middle West USA Postmenopausal Vaginal Atrophy Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
1.5.4 Northeast USA Postmenopausal Vaginal Atrophy Drugs Consumption Market Size and Growth Rate from 2016 to 2027
2 Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Market Challenges and Restraints
-
2.1.2 Market Opportunities and Potentials
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape Analysis
-
2.2.1 Industrial Concentration Analysis
-
2.2.2 Porter's Five Forces Analysis of the Industry
-
2.2.3 SWOT Analysis for New Entrants
-
2.3 Coronavirus (COVID-19) Distribution and its Impact on the Industry
3 Segmentation of Postmenopausal Vaginal Atrophy Drugs Market by Types
-
3.1 Products Development Trends of Different Types
-
3.2 Products Types of Major Vendors
-
3.3 Competitive Landscape Analysis of Different Types
-
3.4 Market Size of Postmenopausal Vaginal Atrophy Drugs by Major Types
-
3.4.1 Market Size and Growth Rate of Premarin
-
3.4.2 Market Size and Growth Rate of Vagifem
-
3.4.3 Market Size and Growth Rate of Estrace
-
3.4.4 Market Size and Growth Rate of Estring
-
3.4.5 Market Size and Growth Rate of Femring
4 Segmentation of Postmenopausal Vaginal Atrophy Drugs Market by End-Users
-
4.1 Downstream Client Analysis by End-Users
-
4.2 Competitive Landscape Analysis of Different End-Users
-
4.3 Market Potential Analysis of Different End-Users
-
4.4 Market Size of Postmenopausal Vaginal Atrophy Drugs by Major End-Users
-
4.4.1 Market Size and Growth Rate of Postmenopausal Vaginal Atrophy Drugs in Vaginal Gels
-
4.4.2 Market Size and Growth Rate of Postmenopausal Vaginal Atrophy Drugs in Creams
-
4.4.3 Market Size and Growth Rate of Postmenopausal Vaginal Atrophy Drugs in Tablets
-
4.4.4 Market Size and Growth Rate of Postmenopausal Vaginal Atrophy Drugs in Rings
-
4.4.5 Market Size and Growth Rate of Postmenopausal Vaginal Atrophy Drugs in Patches
5 Market Analysis by Regions
-
5.1 USA Postmenopausal Vaginal Atrophy Drugs Production Analysis by Regions
-
5.2 USA Postmenopausal Vaginal Atrophy Drugs Consumption Analysis by Regions
-
5.3 Coronavirus (COVID-19) Impact on USA Economy
6 West USA Postmenopausal Vaginal Atrophy Drugs Landscape Analysis
-
6.1 West USA Postmenopausal Vaginal Atrophy Drugs Landscape Analysis by Major Types
-
6.2 West USA Postmenopausal Vaginal Atrophy Drugs Landscape Analysis by Major End-Users
7 South USA Postmenopausal Vaginal Atrophy Drugs Landscape Analysis
-
7.1 South USA Postmenopausal Vaginal Atrophy Drugs Landscape Analysis by Major Types
-
7.2 South USA Postmenopausal Vaginal Atrophy Drugs Landscape Analysis by Major End-Users
8 Middle West USA Postmenopausal Vaginal Atrophy Drugs Landscape Analysis
-
8.1 Middle West USA Postmenopausal Vaginal Atrophy Drugs Landscape Analysis by Major Types
-
8.2 Middle West USA Postmenopausal Vaginal Atrophy Drugs Landscape Analysis by Major End-Users
9 Northeast USA Postmenopausal Vaginal Atrophy Drugs Landscape Analysis
-
9.1 Northeast USA Postmenopausal Vaginal Atrophy Drugs Landscape Analysis by Major Types
-
9.2 Northeast USA Postmenopausal Vaginal Atrophy Drugs Landscape Analysis by Major End-Users
10 Major Players Profiles
-
10.1 Actavis plc
-
10.1.1 Actavis plc Company Profile and Recent Development
-
10.1.2 Market Performance
-
10.1.3 Product and Service Introduction
-
10.2 Novo Nordisk A/S
-
10.2.1 Novo Nordisk A/S Company Profile and Recent Development
-
10.2.2 Market Performance
-
10.2.3 Product and Service Introduction
-
10.3 Shionogi & Company
-
10.3.1 Shionogi & Company Company Profile and Recent Development
-
10.3.2 Market Performance
-
10.3.3 Product and Service Introduction
-
10.4 Allergan plc
-
10.4.1 Allergan plc Company Profile and Recent Development
-
10.4.2 Market Performance
-
10.4.3 Product and Service Introduction
The List of Tables and Figures
-
Figure Product Picture
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Premarin from 2016 to 2027
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Vagifem from 2016 to 2027
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Estrace from 2016 to 2027
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Estring from 2016 to 2027
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Femring from 2016 to 2027
-
Figure Market Share by Type in 2016
-
Figure Market Share by Type in 2020
-
Figure Market Share by Type in 2027
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Vaginal Gels from 2016 to 2027
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Creams from 2016 to 2027
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Tablets from 2016 to 2027
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Rings from 2016 to 2027
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Market Size and Growth Rate of Patches from 2016 to 2027
-
Figure Market Share by End-User in 2016
-
Figure Market Share by End-User in 2020
-
Figure Market Share by End-User in 2027
-
Figure West USA Postmenopausal Vaginal Atrophy Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure South USA Postmenopausal Vaginal Atrophy Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Middle West USA Postmenopausal Vaginal Atrophy Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Northeast USA Postmenopausal Vaginal Atrophy Drugs Consumption Market Size and Growth Rate from 2016 to 2027
-
Figure Development Trends and Industry Dynamics of Postmenopausal Vaginal Atrophy Drugs Industry
-
Figure Market Challenges and Restraints
-
Figure Market Opportunities and Potentials
-
Table Mergers and Acquisition
-
Figure Market Share of TOP 3 Players in 2019
-
Figure Market Share of TOP 5 Players in 2019
-
Figure Market Share of TOP 6 Players from 2016 to 2020
-
Figure Porter's Five Forces Analysis
-
Figure New Entrant SWOT Analysis
-
Figure Coronavirus (COVID-19) Distribution Map of USA
-
Table Coronavirus (COVID-19) Impact on the Industry
-
Figure Specifications of Different Types of Postmenopausal Vaginal Atrophy Drugs
-
Figure Development Trends of Different Types
-
Table Products Types of Major Vendors
-
Figure Competitive Landscape Analysis of Different Types
-
Table Consumption of Postmenopausal Vaginal Atrophy Drugs by Different Types from 2016 to 2027
-
Table Consumption Share of Postmenopausal Vaginal Atrophy Drugs by Different Types from 2016 to 2027
-
Figure Market Size and Growth Rate of Premarin
-
Figure Market Size and Growth Rate of Vagifem
-
Figure Market Size and Growth Rate of Estrace
-
Figure Market Size and Growth Rate of Estring
-
Figure Market Size and Growth Rate of Femring
-
Table Downstream Client Analysis by End-Users
-
Figure Competitive Landscape Analysis of Different End-Users
-
Table Market Potential Analysis of Different End-Users
-
Figure Consumption of Postmenopausal Vaginal Atrophy Drugs by Different End-Users from 2016 to 2027
-
Table Consumption Share of Postmenopausal Vaginal Atrophy Drugs by Different End-Users from 2016 to 2027
-
Figure Market Size and Growth Rate of Vaginal Gels
-
Figure Market Size and Growth Rate of Creams
-
Figure Market Size and Growth Rate of Tablets
-
Figure Market Size and Growth Rate of Rings
-
Figure Market Size and Growth Rate of Patches
-
Table USA Postmenopausal Vaginal Atrophy Drugs Production by Regions
-
Table USA Postmenopausal Vaginal Atrophy Drugs Production Share by Regions
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Production Share by Regions in 2016
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Production Share by Regions in 2021
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Production Share by Regions in 2027
-
Table USA Postmenopausal Vaginal Atrophy Drugs Consumption by Regions
-
Table USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Regions
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Regions in 2016
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Regions in 2021
-
Figure USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Regions in 2027
-
Table West USA Postmenopausal Vaginal Atrophy Drugs Consumption by Types from 2016 to 2027
-
Table West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types from 2016 to 2027
-
Figure West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types in 2016
-
Figure West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types in 2021
-
Figure West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types in 2027
-
Table West USA Postmenopausal Vaginal Atrophy Drugs Consumption by End-Users from 2016 to 2027
-
Table West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users in 2016
-
Figure West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users in 2021
-
Figure West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users in 2027
-
Table South USA Postmenopausal Vaginal Atrophy Drugs Consumption by Types from 2016 to 2027
-
Table South USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types from 2016 to 2027
-
Figure South USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types in 2016
-
Figure South USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types in 2021
-
Figure South USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types in 2027
-
Table South USA Postmenopausal Vaginal Atrophy Drugs Consumption by End-Users from 2016 to 2027
-
Table South USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure South USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users in 2016
-
Figure South USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users in 2021
-
Figure South USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users in 2027
-
Table Middle West USA Postmenopausal Vaginal Atrophy Drugs Consumption by Types from 2016 to 2027
-
Table Middle West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types from 2016 to 2027
-
Figure Middle West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types in 2016
-
Figure Middle West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types in 2021
-
Figure Middle West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types in 2027
-
Table Middle West USA Postmenopausal Vaginal Atrophy Drugs Consumption by End-Users from 2016 to 2027
-
Table Middle West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Middle West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users in 2016
-
Figure Middle West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users in 2021
-
Figure Middle West USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users in 2027
-
Table Northeast USA Postmenopausal Vaginal Atrophy Drugs Consumption by Types from 2016 to 2027
-
Table Northeast USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types from 2016 to 2027
-
Figure Northeast USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types in 2016
-
Figure Northeast USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types in 2021
-
Figure Northeast USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by Types in 2027
-
Table Northeast USA Postmenopausal Vaginal Atrophy Drugs Consumption by End-Users from 2016 to 2027
-
Table Northeast USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users from 2016 to 2027
-
Figure Northeast USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users in 2016
-
Figure Northeast USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users in 2021
-
Figure Northeast USA Postmenopausal Vaginal Atrophy Drugs Consumption Share by End-Users in 2027
-
Table Company Profile and Development Status of Actavis plc
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Actavis plc
-
Figure Sales and Growth Rate Analysis of Actavis plc
-
Figure Revenue and Market Share Analysis of Actavis plc
-
Table Product and Service Introduction of Actavis plc
-
Table Company Profile and Development Status of Novo Nordisk A/S
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novo Nordisk A/S
-
Figure Sales and Growth Rate Analysis of Novo Nordisk A/S
-
Figure Revenue and Market Share Analysis of Novo Nordisk A/S
-
Table Product and Service Introduction of Novo Nordisk A/S
-
Table Company Profile and Development Status of Shionogi & Company
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Shionogi & Company
-
Figure Sales and Growth Rate Analysis of Shionogi & Company
-
Figure Revenue and Market Share Analysis of Shionogi & Company
-
Table Product and Service Introduction of Shionogi & Company
-
Table Company Profile and Development Status of Allergan plc
-
Table Sales, Revenue, Sales Price and Gross Margin Analysis of Allergan plc
-
Figure Sales and Growth Rate Analysis of Allergan plc
-
Figure Revenue and Market Share Analysis of Allergan plc
-
Table Product and Service Introduction of Allergan plc
-
